435 Studies Now Enrolling
A phase III, randomized, open-label, active controlled, multicenter study to evaluate maintenance of response, safety and patient reported outcomes in acromegaly patients treated with octreotide capsules, and in patients treated with standard of care parenteral somatostatin receptor ligands who previously tolerated and demonstrated a biochemical control on both treatments
A study for patients with acromegaly using study drug Octreotide
| Sponsor: | Chiasma |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAQ3353 |
| U.S. Govt. ID: | NCT02685709 |
| Contact: | Pamela Freda: 212-305-2254 / puf1@cumc.columbia.edu |
Additional Study Information:
This study is for patients who have been diagnosed with acromegaly and have been treated with the injectable medications ocreotide or lanreotide for at least 6 months. You should have had the same dose for at least 4 months, and be adequately controlled. The purpose of this study is to compare the safety and effectiveness of an investigational new drug product, octreotide capsules, to injectable octreotide and lanreotide in patients with acromegaly.
This study is closed
